Novartis to develop transdermal insulin
Melbourne, Australia -- Novartis Animal Health signed an agreement March 31 with Australian pharmaceutical company Phosphagenics Ltd. to develop a transdermal insulin delivery system for pets.
Melbourne, Australia
-- Novartis Animal Health signed an agreement March 31 with Australian pharmaceutical company Phosphagenics Ltd. to develop a transdermal insulin delivery system for pets.
The formulation and potential product is still in the planning stages. But a Phosphagenics spokesperson touted the potential benefits of trandermal-applied insulin: more user-friendly than injections, improving client compliance and the use of insulin for companion animals.
Novartis will pay to develop the product and compensate Phosphagenics with additional royalties and milestone payments if the product is released in the market.
Newsletter
From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
